B
SLXP

Barings’s SALIX PHARMACEUTICALS LTD DEL SLXP Stock Holding History

Barings’s Portfolio SLXP Stock Details SLXP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q2 		– Sell
-9,000
Closed -$932K – 1041
2014
Q1 		$932K Buy
9,000
+5,400
+150% +$553K 0.03% 483
2013
Q4 		$324K Sell
3,600
-1,300
-27% -$104K 0.01% 727
2013
Q3 		$328K Buy
+4,900
New +$338K 0.01% 732

Other funds holding SLXP

Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
TCIM
TIAA CREF Investment Management New York $141B AUM 14.18% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VAM
Visium Asset Management New York $1.43B AUM 3.58% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

Barings's SLXP Position: Q2 2014 in Review

Barings sold out of SALIX PHARMACEUTICALS LTD DEL (SLXP) in Q2 2014, closing a stake of 9,000 shares — an estimated $932K sold.

Barings first reported a position in SLXP in Q3 2013 and held it in 3 quarters. The position peaked at $932K in Q1 2014. 308 funds tracked by Wall St. Rank hold SLXP as of Q2 2014.

  • Barings reported no remaining SALIX PHARMACEUTICALS LTD DEL position as of Q2 2014 after selling out during the quarter.
  • Barings sold 9,000 SALIX PHARMACEUTICALS LTD DEL shares in Q2 2014, an estimated $932K.
  • Barings first reported a position in SALIX PHARMACEUTICALS LTD DEL in Q3 2013 and held it in 3 quarters.
  • Barings's SALIX PHARMACEUTICALS LTD DEL position peaked at $932K in Q1 2014.
  • 308 funds tracked by Wall St. Rank held SALIX PHARMACEUTICALS LTD DEL as of Q2 2014.

Based on Barings's 13F filing for Q2 2014, filed 8 Aug 2014.